Yael Mossé Laboratory News Updates
1 - 4 of 4
CHOP recipient, physician-scientist Dr. Yael Mossé, is innovating targeted, less toxic therapies for cancer affecting mostly infants and young children.
CHOP researchers have identified a powerful new drug with “unparalleled” strength against refractory types of neuroblastoma.
CHOP Is a Founding Member of New NIH-Funded Research Consortium to Test New Cancer Treatments for Children
Building on its decades-long investigations in the biology and treatment of neuroblastoma, CHOP will lead the consortium’s neuroblastoma research program.
CHOP and Penn Medicine experts are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations, setting the stage for a phase 3 clinical trial.